The HER-2 Negative Breast Cancer Market is segmented By Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, and Others), By Distribution Channel (Public Hospitals and Private Hospitals, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America) - Global Opportunity Analysis and Industry Forecast, 2023-2030. 
Global HER-2 Negative Breast Cancer Market
The global HER-2 negative breast cancer market was valued at USD 12,402 million by 2022 which expected to reach USD 27,443.15 million by 2030, at a CAGR 8.67% from 2023-2030.
Human epidermal growth factor receptor-2 is known as HER-2. In moderation, it's beneficial, but in excess, it could signal a particular type of breast cancer. If people with breast cancer have a normal amount of HER-2, which called as HER2-negative breast cancer.
Market Drivers
The incidence and prevalence of breast cancer are rising quickly as a result of lifestyle changes, and a number of factors—including age, obesity, alcohol abuse, radiation exposure history, family history of breast cancer, family history of the disease, age at first pregnancy, menstrual cycle onset, and tobacco use—increase the risk of developing the disease. For instance, about 15–20% of all breast cancer cases in the United States, as reported by the National Institutes of Health in March 2022, were HER-2 Negative. In 2022, 287,850 new instances of female breast cancer are projected to be discovered.
In addition, according to the Global Cancer Observatory's (Globocan) 2020 report, breast cancer was the most common type of cancer globally in that year. In 2020, there were approximately 2,261,419 new cases of breast cancer. By 2040, there are anticipated to be 3,025,471 new cases of breast cancer, up from 2,261,419 in 2020. According to this research, the incidence of breast cancer is rising globally. As a result, over the course of the study's forecast period, it is anticipated that the HER-2-negative breast cancer market will expand due to the rising incidence of breast cancer worldwide. 
Moreover, the leading players in the market are expanding their product approval and pipeline products as a result of the expanding research and development activities in the field, which is further predicted to have a substantial impact on the segment's growth over the projected period. For instance, in October 2021, the American FDA approved abemaciclib (Verzenio) in combination with endocrine therapy (either tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, breast cancer who are at high risk of recurrence and a Ki-67 score of 20% or less, as determined by an FDA approved test.
These driving forces will likely accelerate market growth over the anticipated period.
Market Restraints
The market expansion during the anticipated period may be hampered by a lack of skilled professionals for operating with intracranial stents. Additionally, Cerebrovascular Complications Related to Intracranial Stenting could restrict market expansion.
Market Segmentation
The global HER-2 negative breast cancer market is segmented into type of treatment such as Chemotherapy, Radiation, Hormonal Therapy, and Others. Further, the market is segmented into distribution channels such as Public Hospitals and Private Hospitals, and Ambulatory Surgical Centers.
Regional Analysis
The major regions covered in the global HER-2 negative breast cancer market are North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
In recognition of the region's improved healthcare infrastructure and the rising number of foundations and independent venture firms supporting the biopharmaceutical industry, North America is anticipated to account for a sizeable portion of the global market for HER-2 negative breast cancer.
Recent Developments
•        In September 2022, Novartis released findings from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer. (aBC).
•        In May 2022, Pfizer reported strong Real-World Evidence for IBRANCE (palbociclib) combination therapy as first-line treatment for HR+, HER2-metastatic breast cancer at the ESMO Breast Cancer 2022 conference.
Key Players
Pfizer, Novartis AG, Merck & Co., Inc., GlasxoSmithKline, Eli Lilly and Company, Bristol Myers Squibb Company (Celgene Corporation), AstraZeneca PLC, Lupin, Bayer AG, etc. are some of the major companies mentioned in this report study.
Market Taxonomy
By Treatment
•        Chemotherapy
•        Radiation
•        Hormonal Therapy
•        Others
By Distribution Channel
•        Public Hospitals and Private Hospitals
•        Ambulatory Surgical Centers
By Region
•        North America (U.S. Canada, Mexico)
•        Latin America (Brazil, Rest of Latin America)
•        Europe (Germany, UK, Italy, France, Rest of Europe
•        Asia Pacific (China, India, Japan, Rest of Asia Pacific)
•        Middle East & Africa (Saudi Arabia, Kuwait, UAE, Egypt, South Africa)

Global HER-2 Negative Breast Cancer Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global HER-2 Negative Breast Cancer Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global HER-2 Negative Breast Cancer Market, By Treatment
5.1 Y-o-Y Growth Comparison, By Treatment
5.2 Global HER-2 Negative Breast Cancer Market Share Analysis, By Treatment
5.3 Global HER-2 Negative Breast Cancer Market Size and Forecast, By Treatment
5.3.1 Chemotherapy
5.3.2. Radiation
5.3.3. Hormonal Therapy
5.3.4. Others
6 Global HER-2 Negative Breast Cancer Market, By Distribution Channel
6.1 Y-o-Y Growth Comparison, By Distribution Channel
6.2 Global HER-2 Negative Breast Cancer Market Share Analysis, By Distribution Channel
6.3 Global HER-2 Negative Breast Cancer Market Size and Forecast, By Distribution Channel
6.3.1 Public Hospitals and Private Hospitals
6.3.2 Ambulatory Surgical Centers
7 Global HER-2 Negative Breast Cancer Market, By Region
7.1 Global HER-2 Negative Breast Cancer Market Share Analysis, By Region
7.2 Global HER-2 Negative Breast Cancer Market Size and Forecast, By Region
8 North America HER-2 Negative Breast Cancer Market Analysis and Forecast (2023-2030)
8.1 Introduction
8.2 North America HER-2 Negative Breast Cancer Market Share Analysis, By Treatment
8.3 North America HER-2 Negative Breast Cancer Market Size and Forecast, By Distribution Channel
8.4 North America HER-2 Negative Breast Cancer Market Size and Forecast, By Country
8.4.1 U.S.
8.4.2 Canada
8.4.3 Mexico
9 Europe HER-2 Negative Breast Cancer Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 Europe HER-2 Negative Breast Cancer Market Share Analysis, By Treatment
9.3 Europe HER-2 Negative Breast Cancer Market Size and Forecast, By Distribution Channel
9.4 Europe HER-2 Negative Breast Cancer Market Size and Forecast, By Country
9.4.1 Germany
9.4.2 France
9.4.3 UK
9.4.4 Rest of Europe
10 Asia Pacific HER-2 Negative Breast Cancer Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Asia Pacific HER-2 Negative Breast Cancer Market Share Analysis, By Treatment
10.3 Asia Pacific HER-2 Negative Breast Cancer Market Size and Forecast, By Distribution Channel
10.4 Asia Pacific HER-2 Negative Breast Cancer Market Size and Forecast, By Country
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia
11 Latin America HER-2 Negative Breast Cancer Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Latin America HER-2 Negative Breast Cancer Market Share Analysis, By Treatment
11.3 Latin America HER-2 Negative Breast Cancer Market Size and Forecast, By Distribution Channel
11.4 Latin America HER-2 Negative Breast Cancer Market Size and Forecast, By Country
11.4.1 Brazil
11.4.2 Rest of Latin America
12 Middle East HER-2 Negative Breast Cancer Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Middle East HER-2 Negative Breast Cancer Market Share Analysis, By Treatment
12.3 Middle East HER-2 Negative Breast Cancer Market Size and Forecast, By Distribution Channel
12.4 Middle East HER-2 Negative Breast Cancer Market Size and Forecast, By Country
12.4.1 Saudi Arabia
12.4.2 UAE
12.4.3 Egypt
15.4.4 Kuwait
12.4.5 South Africa
13 Competitive Analysis
13.1 Competition Dashboard
13.2 Market share Analysis of Top Vendors
13.3 Key Development Strategies
14 Company Profiles
14.1 Pfizer
14.1.1 Overview
14.1.2 Offerings
14.1.3 Key Financials
14.1.4 Business Segment & Geographic Overview
14.1.5 Key Market Developments
14.1.6 Key Strategies
14.2 Novartis AG
14.2.1 Overview
14.2.2 Offerings
14.2.3 Key Financials
14.2.4 Business Segment & Geographic Overview
14.2.5 Key Market Developments
14.2.6 Key Strategies
14.3 Merck & Co., Inc
14.3.1 Overview
14.3.2 Offerings
14.3.3 Key Financials
14.3.4 Business Segment & Geographic Overview
14.3.5 Key Market Developments
14.3.6 Key Strategies
14.4 GlasxoSmithKline
14.4.1 Overview
14.4.2 Offerings
14.4.3 Key Financials
14.4.4 Business Segment & Geographic Overview
14.4.5 Key Market Developments
14.4.6 Key Strategies
14.5 Eli Lilly and Company
14.5.1 Overview
14.5.2 Offerings
14.5.3 Key Financials
14.5.4 Business Segment & Geographic Overview
14.5.5 Key Market Developments
14.5.6 Key Strategies
14.6 Bristol Myers Squibb Company (Celgene Corporation)
14.6.1 Overview
14.6.2 Offerings
14.6.3 Key Financials
14.6.4 Business Segment & Geographic Overview
14.6.5 Key Market Developments
14.6.6 Key Strategies
14.7 AstraZeneca PLC
14.7.1 Overview
14.7.2 Offerings
14.7.3 Key Financials
14.7.4 Business Segment & Geographic Overview
14.7.5 Key Market Developments
14.7.6 Key Strategies
14.8 Lupin
14.8.1 Overview
14.8.2 Offerings
14.8.3 Key Financials
14.8.4 Business Segment & Geographic Overview
14.8.5 Key Market Developments
14.8.6 Key Strategies
14.9 Bayer AG
14.9.1 Overview
14.9.2 Offerings
14.9.3 Key Financials
14.9.4 Business Segment & Geographic Overview
14.9.5 Key Market Developments
14.9.6 Key Strategies